Oncimmune Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Oncimmune Holdings es Martin Gouldstone, nombrado en Aug 2023, tiene una permanencia de 1.25 años. posee directamente un 0.049% de las acciones de la empresa, con un valor de £5.55K. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 5.6 años, respectivamente.

Información clave

Martin Gouldstone

Chief Executive Officer (CEO)

UK£21.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.3yrs
Participación del CEO	0.05%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Aug 16

CEO

Martin Gouldstone (58 yo)

1.3yrs

Permanencia

UK£21,000

Compensación

Mr. Martin John Gouldstone is Chief Executive Officer and Director of Oncimmune Holdings plc from August 1, 2023. He serves as an Independent Non-Executive Director of ValiRx Plc since April 22, 2024 and s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Gouldstone	CEO & Director	1.3yrs	UK£21.00k	0.049% £ 5.5k
Ron Kirschner	COO, General Counsel & Company Secretary	4.6yrs	UK£27.00k	sin datos
Martin Hudson	Finance Director	1.2yrs	sin datos	sin datos
Tariq Sethi	Chief Scientific Officer	5.1yrs	sin datos	sin datos
Cléa Rosenfeld	Head of Investor Relations	5.3yrs	sin datos	sin datos
Maarten Brusse	Chief Commercial Officer of Asia	8.2yrs	sin datos	sin datos

4.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de ONC se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Gouldstone	CEO & Director	1.3yrs	UK£21.00k	0.049% £ 5.5k
Alistair Macdonald	Non-executive Chairman	2.3yrs	UK£100.00k	0.075% £ 8.6k
John Goold	Independent Non-Executive Director	1.8yrs	UK£15.00k	1.55% £ 177.1k
Parag Mallick	Member of Scientific Board	5.6yrs	sin datos	sin datos
Richard Roope	Member of Scientific Board	5.9yrs	sin datos	sin datos
Nora Pashayan	Member of Scientific Board	5.9yrs	sin datos	sin datos
Ola Winqvist	Member of Scientific Board	5.9yrs	sin datos	sin datos

5.6yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de ONC se considera experimentada (5.6 años de antigüedad promedio).

Oncimmune Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Recent updates

No longer forecast to breakeven

New major risk - Financial data availability

Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025

New major risk - Negative shareholders equity

New major risk - Share price stability

Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024

Less than half of directors are independent

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

New major risk - Share price stability

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

New minor risk - Financial data availability

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director

Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.

Less than half of directors are independent

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Oncimmune Holdings plc Announces Board Changes

Price target increased to UK£2.22

Less than half of directors are independent

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Oncimmune Holdings Ordinary Shares to Be Deleted from Other OTC

Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain

Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)

Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles

Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting

New 90-day high: UK£1.94

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)

Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021

Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021

New 90-day high: UK£1.90

Oncimmune Holdings plc Signs Commercial Contracts

Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020

Annual earnings released: Earnings beat expectations, revenue disappoints

Full year earnings released - UK£0.13 loss per share

Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020

New 90-day high: UK£1.73

Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma

Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors

Oncimmune Holdings plc Signs Collaboration with Genentech

New 90-day high - UK£1.51

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad